Objective To investigate the clinical effect and safety of amisulpride combined with venlafaxine in the treatment ofseniledepression.Methods 92patientswithseniledepressionwererandomlydividedintostudygroup(47cases)treated with amisulpride combined with venlafaxine for 6 weeks and control group (45 cases) treated with venlafaxine monotherapy for 6 weeks.Curative effect and side effect were evaluated with Hamilton Depression Rating Scale-17 items ( HAMD-17 ) and Treatment Emergent Symptom Scale ( TESS) respectively at baseline and at the end of the 1st, 2nd, 4th, 6th week of the treatment.Results Total scores of HAMD-17 in both groups decreased significantly at the end of the 1st, 2nd, 4th, 6th week compared with the baseline (P<0.05), and total scores of HAMD-17 in study group were significantly lower than those in control group at the end of the 2nd, 4thand 6th week of the treatment (P<0.05).At the end of the 6th week, all factor scores of HAMD-17 except the factor of weight in both groups decreased significantly compared with the baseline (P<0.05), and factor scores mentioned above in study group were significantly lower than those in control group (P<0.05).There was no significant difference in incidence of adverse reactions between the two groups ( P >0.05).Conclusion Amisulpride combined with venlafaxine is more effective than venlafaxine monotherapy in the treatment of senile depression without the extra increase of side effects.%目的：探讨氨磺必利联合文拉法辛治疗老年期抑郁症的临床疗效和安全性。方法将92例老年抑郁症患者随机分为氨磺必利联合文拉法辛组（研究组）47例和文拉法辛组（对照组）45例，治疗并观察6周。于治疗前及治疗后第1、2、4和6周末采用17项汉密尔顿抑郁量表（HAMD-17）评定疗效，用治疗中需处理的不良反应症状量表（TESS）评定药物不良反应。结果治疗后第1、2、4、6周末两组患者HAMD-17评分均较各自治疗前降低（ P＜0．05），且治疗后第2、4、6周末研究组HAMD-17评分均低于对照组（P＜0．05）。治疗后第6周末，两组患者HAMD-17各因子分（体质量因子除外）均较各自治疗前降低（P＜0．05），且研究组低于对照组（P＜0．05）。两组间药物不良反应发生率比较差异无统计学意义（P＞0．05）。结论氨磺必利联合文拉法辛治疗老年期抑郁症的疗效优于单用文拉法辛，且不良反应并未增加。
展开▼
